David T. Curiel

39.2k citations

595 papers · 28.6k indexed · 5 hit papers · h-index 86

Molecular Biology top 0.1%
Genetics top 0.01%
Oncology top 0.05%
Immunology top 0.5%
Biotechnology top 0.02%

Co-authors: Victor Krasnykh Igor P. Dmitriev Ramón Alemany Joanne T. Douglas Galina Mikheeva Ronald D. Alvarez Gene P. Siegal Minghui Wang
Topics: Virus-based gene therapy research (454 papers)CAR-T cell therapy research (226 papers)Viral Infectious Diseases and Gene Expression in Insects (176 papers)
Cited by: Genetics Oncology Biotechnology
Journals: Proceedings of the National Academy of Sciences Nucleic Acids Research Journal of Biological Chemistry
Partner nations: United States France Netherlands

In The Last Decade

David T. Curiel

589 papers receiving 27.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An Adenovirus Vector with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-Independent Cell Entry Mechanism

1998 639 citations Igor P. Dmitriev, Minghui Wang et al. profile →
Engineering targeted viral vectors for gene therapy

2007 549 citations David T. Curiel et al. profile →
Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells

2001 509 citations David T. Curiel, Tyler J. Curiel et al. profile →
COX2/mPGES1/PGE ₂ pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells

2017 374 citations Victor Prima, Lyudmila N. Kaliberova et al. Proceedings of the National Academy of Sciences profile →
Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic

2021 195 citations Samir Andrade Mendonça, Réka Lőrincz et al. profile →

Peers

Countries citing papers authored by David T. Curiel

Since Specialization

Citations

This map shows the geographic impact of David T. Curiel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David T. Curiel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David T. Curiel more than expected).

Fields of papers citing papers by David T. Curiel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David T. Curiel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David T. Curiel. The network helps show where David T. Curiel may publish in the future.

Co-authorship network of co-authors of David T. Curiel

This figure shows the co-authorship network connecting the top 25 collaborators of David T. Curiel. A scholar is included among the top collaborators of David T. Curiel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David T. Curiel. David T. Curiel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nonreciprocity in CHIKV and MAYV Vaccine-Elicited Protection 2024 ·Vaccines ·(unknown),Takeshi F. Andoh,Craig N. Kreklywich,(unknown),Michael Denton,(unknown),John M. Powers,(unknown),(unknown),Igor P. Dmitriev,David T. Curiel,Nicole N. Haese,Daniel N. Streblow	3
2	In vivo editing of the pan-endothelium by immunity evading simian adenoviral vector 2022 ·Biomedicine & Pharmacotherapy ·Réka Lőrincz,(unknown),Christopher J. Walkey,Samir Andrade Mendonça,Zhi Hong Lu,(unknown),(unknown),Jason D. Heaney,William R. Lagor,David T. Curiel	7
3	Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma 2020 ·Clinical Cancer Research ·(unknown),Katarzyna C. Pituch,Hiroaki Katagi,Μαρκέλλα Ζαννίκου,(unknown),Ting Xiao,Yu Han,Adam M. Sonabend,David T. Curiel,Erin R. Bonner,Javad Nazarian,Craig Horbinski,C. David James,Amanda Saratsis,Rintaro Hashizume,Maciej S. Lesniak,Irina V. Balyasnikova	52
4	COX2/mPGES1/PGE ₂ pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cellsbreakdown → 2017 ·Proceedings of the National Academy of Sciences ·Victor Prima,Lyudmila N. Kaliberova,Sergey A. Kaliberov,David T. Curiel,Sergei Kusmartsev	374
5	A One Health overview, facilitating advances in comparative medicine and translational research 2016 ·Clinical and Translational Medicine ·(unknown),Igor P. Dmitriev,Elena A. Kashentseva,Jeffrey N. Bryan,David T. Curiel,Hans Rindt,Carol R. Reinero,Carolyn J. Henry,Philip J. Bergman,Nicola J. Mason,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	17
6	A Novel CDC25B Promoter–Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models 2015 ·Clinical Cancer Research ·(unknown),Manuel Gidekel,Santiago Werbajh,Edgardo Salvatierra,(unknown),(unknown),(unknown),David T. Curiel,Eduardo G. Cafferata,Osvaldo L. Podhajcer	9
7	A Phase I Clinical Trial of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Patients with Recurrent Gynecologic Cancer 2012 ·Clinical Cancer Research ·Kenneth H. Kim,Igor P. Dmitriev,Janis P. O’Malley,Minghui Wang,Souheil Saddekni,Zhiying You,Meredith A. Preuss,Raymond D. Harris,Rosemarie Aurigemma,Gene P. Siegal,Kurt R. Zinn,David T. Curiel,Ronald D. Alvarez	49
8	Potent Antitumor Immunity Generated by a CD40-Targeted Adenoviral Vaccine 2011 ·Cancer Research ·Basav N. Hangalapura,Dinja Oosterhoff,Jan de Groot,Louis Boon,Thomas Tüting,Alfons J. van den Eertwegh,Winald R. Gerritsen,Victor W. van Beusechem,Alexander Pereboev,David T. Curiel,Rik J. Scheper,Tanja D. de Gruijl	26
9	Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda -7/IL-24–mediated toxicity 2011 ·Proceedings of the National Academy of Sciences ·Rupesh Dash,Belal Azab,Bridget A. Quinn,Xue‐Ning Shen,Xiangyang Wang,Swadesh K. Das,Mohamed Rahmani,Jun Wei,Michael Hedvat,Paul Dent,Igor P. Dmitriev,David T. Curiel,Steven Grant,Bainan Wu,John L. Stebbins,Maurizio Pellecchia,John C. Reed,Devanand Sarkar,Paul B. Fisher	101
10	Mechanism of Autophagy to Apoptosis Switch Triggered in Prostate Cancer Cells by Antitumor Cytokine Melanoma Differentiation-Associated Gene 7/Interleukin-24 2010 ·Cancer Research ·Sujit K. Bhutia,Rupesh Dash,Swadesh K. Das,Belal Azab,Zhao-zhong Su,Seok‐Geun Lee,Steven Grant,Adly Yacoub,Paul Dent,David T. Curiel,Devanand Sarkar,Paul B. Fisher	102
11	PERK–Dependent Regulation of Ceramide Synthase 6 and Thioredoxin Play a Key Role in mda -7/IL-24–Induced Killing of Primary Human Glioblastoma Multiforme Cells 2010 ·Cancer Research ·Adly Yacoub,Hossein A. Hamed,Jeremy C. Allegood,Clint Mitchell,Sarah Spiegel,Maciej S. Lesniak,Besim Öğretmen,Rupesh Dash,Devanand Sarkar,William C. Broaddus,Steven Grant,David T. Curiel,Paul B. Fisher,Paul Dent	89
12	Mechanism by Which Mcl-1 Regulates Cancer-Specific Apoptosis Triggered by mda-7/IL-24, an IL-10–Related Cytokine 2010 ·Cancer Research ·Rupesh Dash,Joanna E. Richards,Zhao-zhong Su,Sujit K. Bhutia,Belal Azab,Mohamed Rahmani,Girija Dasmahapatra,Adly Yacoub,Paul Dent,Igor P. Dmitriev,David T. Curiel,Steven Grant,Maurizio Pellecchia,John C. Reed,Devanand Sarkar,Paul B. Fisher	65
13	Combined Transductional Untargeting/Retargeting and Transcriptional Restriction Enhances Adenovirus Gene Targeting and Therapy for Hepatic Colorectal Cancer Tumors 2009 ·Cancer Research ·Hua‐Jung Li,Maaike Everts,Masato Yamamoto,David T. Curiel,Harvey R. Herschman	22
14	MDA-7/IL-24–induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK–dependent mechanism 2009 ·Molecular Cancer Therapeutics ·Margaret A. Park,Teneille Walker,Aditi Pandya Martin,Jeremy C. Allegood,Nicollaq Vozhilla,Luni Emdad,Devanand Sarkar,Mohamed Rahmani,Martin Graf,Adly Yacoub,Constantinos Koumenis,Sarah Spiegel,David T. Curiel,Christina Voelkel‐Johnson,Steven Grant,Paul B. Fisher,Paul Dent	40
15	Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation 2008 ·Clinical Cancer Research ·Guo Zhang,Margaret A. Park,Clint Mitchell,Hossein A. Hamed,Mohamed Rahmani,Aditi Pandya Martin,David T. Curiel,Adly Yacoub,Martin R. Graf,Ray Lee,John D. Roberts,Paul B. Fisher,Steven Grant,Paul Dent	101
16	Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95 2008 ·Molecular Cancer Therapeutics ·Margaret A. Park,Guo Zhang,Clint Mitchell,Mohamed Rahmani,Hossein A. Hamed,Michael P. Hagan,Adly Yacoub,David T. Curiel,Paul B. Fisher,Steven Grant,Paul Dent	41
17	Ionizing radiation enhances adenoviral vector expressing mda‐7/IL‐24‐mediated apoptosis in human ovarian cancer 2006 ·Journal of Cellular Physiology ·Luni Emdad,Devanand Sarkar,Irina V. Lebedeva,(unknown),Pankaj Gupta,Parameshwar J. Mahasreshti,Paul Dent,David T. Curiel,Paul B. Fisher	33
18	Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures 2004 ·Molecular Cancer Therapeutics ·N. Sanjib Banerjee,Ángel A. Rivera,Minghui Wang,Louise T. Chow,Thomas R. Broker,David T. Curiel,Dirk M. Nettelbeck	46
19	Tumor immunotherapy: inching toward the finish line 2002 ·Journal of Clinical Investigation ·Tyler J. Curiel,David T. Curiel	11
20	Tumor immunotherapy: inching toward the finish line 2002 ·Journal of Clinical Investigation ·Tyler J. Curiel,David T. Curiel	1

About David T. Curiel

David T. Curiel is a scholar working on Genetics, Oncology and Biotechnology, having authored 595 papers that have together received 28.6k indexed citations. Recurring topics across this work include Virus-based gene therapy research (454 papers), CAR-T cell therapy research (226 papers) and Viral Infectious Diseases and Gene Expression in Insects (176 papers). The work is most often cited by research in Genetics (17.4k citations), Oncology (11.0k citations) and Biotechnology (3.2k citations). David T. Curiel has collaborated with scholars based in United States, France and Netherlands. Frequent co-authors include Victor Krasnykh, Igor P. Dmitriev, Ramón Alemany, Joanne T. Douglas, Galina Mikheeva, Ronald D. Alvarez, Gene P. Siegal, Minghui Wang, Elena A. Kashentseva and Masato Yamamoto. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact